- Home
- INMB vs CTNM Comparison
INMB vs CTNM Comparison
Compare INMB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- CTNM
- Stock Information
- Founded
- INMB 2015
- CTNM 2009
- Country
- INMB United States
- CTNM United States
- Employees
- INMB N/A
- CTNM N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- CTNM
- Sector
- INMB Health Care
- CTNM
- Exchange
- INMB Nasdaq
- CTNM Nasdaq
- Market Cap
- INMB 203.5M
- CTNM 199.3M
- IPO Year
- INMB 2019
- CTNM 2024
- Fundamental
- Price
- INMB $8.59
- CTNM $7.59
- Analyst Decision
- INMB Strong Buy
- CTNM Strong Buy
- Analyst Count
- INMB 2
- CTNM 4
- Target Price
- INMB $21.50
- CTNM $29.25
- AVG Volume (30 Days)
- INMB 462.2K
- CTNM 56.2K
- Earning Date
- INMB 03-27-2025
- CTNM 03-04-2025
- Dividend Yield
- INMB N/A
- CTNM N/A
- EPS Growth
- INMB N/A
- CTNM N/A
- EPS
- INMB N/A
- CTNM N/A
- Revenue
- INMB $42,000.00
- CTNM N/A
- Revenue This Year
- INMB N/A
- CTNM N/A
- Revenue Next Year
- INMB N/A
- CTNM N/A
- P/E Ratio
- INMB N/A
- CTNM N/A
- Revenue Growth
- INMB N/A
- CTNM N/A
- 52 Week Low
- INMB $4.32
- CTNM $7.04
- 52 Week High
- INMB $13.52
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- INMB 51.55
- CTNM N/A
- Support Level
- INMB $8.90
- CTNM N/A
- Resistance Level
- INMB $9.58
- CTNM N/A
- Average True Range (ATR)
- INMB 0.93
- CTNM 0.00
- MACD
- INMB -0.20
- CTNM 0.00
- Stochastic Oscillator
- INMB 16.23
- CTNM 0.00
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.